Blog
RSS FeedPosted by Michael Wonder on 09 Nov 2017
NICE turns down Bayer’s Stivarga for liver cancer
8 November 2017 - Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced ...
Posted by Michael Wonder on 03 Nov 2017
ICR responds to Government report produced following Accelerated Access Review
3 November 2017 - The Institute of Cancer Research, London, today responds to the Government’s announcement of a new, fast-track ...
Posted by Michael Wonder on 01 Nov 2017
NICE back Roche’s Tecentriq for CDF
1 November 2017 - The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the ...
Posted by Michael Wonder on 23 Oct 2017
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
23 October 2017 - NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar ...
Posted by Michael Wonder on 20 Oct 2017
NICE no for Opdivo in urothelial carcinoma
20 October 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for ...
Posted by Michael Wonder on 16 Oct 2017
Roche’s skin cancer drug Erivedge pulled from CDF
13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute ...
Posted by Michael Wonder on 12 Oct 2017
New treatment option for people with gastro-intestinal cancer
12 October 2017 - More people will be able to receive regorafenib now that NICE has said it should move out ...
Posted by Michael Wonder on 07 Oct 2017
Leukaemia patients to get access to AbbVie’s Venclyxto via Cancer Drugs Fund
5 October 2017 - AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the ...
Posted by Michael Wonder on 28 Sep 2017
NICE knocks-back Janssen's Imbruvica in Mantle cell lymphoma
28 September 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). ...
Posted by Michael Wonder on 20 Sep 2017
Nivolumab now available for lung cancer after company offers NICE new CDF deal
20 September 2017 - Around 1,300 lung cancer patients will receive nivolumab as part of a CDF deal put forward ...
Posted by Michael Wonder on 18 Sep 2017
NICE rejects first-line use of Roche’s Gazyvaro
18 September 2017 - The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro ...
Posted by Michael Wonder on 06 Sep 2017
NICE publishes updated guidance on the use of Nexavar on the NHS
6 September 2017 - NICE has updated its 2010 guidance on the use of sorafenib tosylate (Nexavar) on the NHS ...
Posted by Michael Wonder on 05 Sep 2017
NICE publishes second draft guidance for ixazomib citrate
5 September 2017 - The Department of Health has asked NICE to produce guidance on use of ixazomib citrate (Ninlaro) in ...
Posted by Michael Wonder on 04 Sep 2017
Merck’s Erbitux backed by NICE for head and neck cancer
4 September 2017 - Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell ...
Posted by Michael Wonder on 01 Sep 2017
NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
1 September 2017 - NICE has published draft guidance saying the evidence on using fulvestrant to treat a type of breast ...